Latest 10-Q quarterly reports

Lipocine Inc. reported Q1 2026 results, highlighting a significant setback in its LPCN 1154 Phase 3 trial for postpartum depression, while continuing to advance other pipeline candidates and manage existing licensing agreements.

Theravance Biopharma announced first-quarter 2026 financial results, reporting a net loss of $4.9 million, and confirmed the wind-down of its ampreloxetine program following unsuccessful Phase 3 trial results.

Loar Holdings reported a significant increase in net sales for Q1 2026, driven by recent acquisitions, though net income saw a decrease due to higher interest and amortization expenses.

Universal Technical Institute (UTI) reported a 6.7% revenue increase for the second quarter of fiscal year 2026, driven by higher student enrollment and new program launches, despite increased strategic growth expenses.

Privia Health Group, Inc. has amended its credit agreement to increase the revolving credit commitment and extend the maturity date.

SM Energy Company reported a net loss for the first quarter of 2026, largely due to significant derivative losses, while integrating the recently completed merger with Civitas Resources.

Celsius Holdings reports a significant revenue increase in Q1 2026, driven by the successful integration of Alani Nu and Rockstar acquisitions, alongside strategic partnerships.

Aemetis, Inc. reported a 27.4% increase in total revenue for Q1 2026, driven by strong performance in its Renewable Natural Gas and India Biodiesel segments, though the company continues to face significant liquidity concerns and a substantial debt burden.

Victory Capital Holdings reports a significant increase in Q1 2026 revenue and net income, driven by the successful integration of the Amundi US acquisition and strong AUM growth.

Vericel Corporation announced a 30.1% increase in total revenue for the first quarter of 2026, driven by significant growth in MACI and Epicel sales.

InspireMD, Inc. reported a 122% revenue increase for Q1 2026 driven by CGuard Prime's US launch, but faces substantial doubt about its ability to continue as a going concern.

Evolent Health reported a 2.6% revenue increase in Q1 2026, driven by new contracts, but saw its net loss widen due to higher claims costs and increased interest expenses.

Playtika Holding Corp. reported a net loss for Q1 2026, with revenues increasing year-over-year, driven by SuperPlay titles, while facing increased sales and marketing expenses and significant legal challenges.

The Macerich Company's Q1 2026 Form 10-Q filing details a net loss of $36.35 million, a decrease from the prior year, alongside strategic portfolio adjustments and a strengthened credit facility.

Ecolab Inc. announced a 10% increase in net sales for the first quarter of 2026, driven by strong performance across its segments and the positive impact of recent acquisitions.

Patrick Industries reported a marginal 1% decrease in net sales for the first quarter of 2026, with net income seeing a modest 3% increase.

Inspired Entertainment reports a 5% revenue decrease in Q1 2026 compared to Q1 2025, primarily due to the sale of its UK holiday parks business, but sees improved net operating income.

Kulicke & Soffa reports a significant increase in Q2 2026 revenue and a strong return to profitability, driven by robust performance in Ball Bonding Equipment.

Cadrenal Therapeutics reports a 35% reduction in net loss for Q1 2026, driven by decreased operating expenses, but faces substantial doubt regarding its ability to continue as a going concern.

ScanSource, Inc. announced its financial results for the third quarter of fiscal year 2026, reporting an 8.8% increase in net sales to $766.8 million, driven by growth in its Specialty Technology Solutions segment.

Palvella Therapeutics reports a significant increase in R&D expenses for Q1 2026, alongside a substantial cash infusion from a recent equity financing.

AquaBounty Technologies reports a net loss of $1.2 million for Q1 2026, with ongoing concerns about its ability to continue as a going concern.

Aurinia Pharmaceuticals Inc. announced a significant increase in net product sales and improved operating income for the first quarter of 2026, driven by strong performance of LUPKYNIS.

Silence Therapeutics plc reported a net loss of $14.96 million for Q1 2026, with a significant decrease in R&D costs and a cash runway extending into 2028.

Harmony Biosciences reported a 16.6% increase in net product revenue for Q1 2026, driven by unit shipments and a price increase, while research and development expenses more than doubled due to significant upfront license fees.

International Seaways reports a significant increase in Q1 2026 net income driven by robust shipping revenues and gains from vessel sales.

CRA International, Inc. reported a 10.5% increase in revenue for the first quarter of fiscal 2026, reaching $201.0 million, though net income saw a decrease compared to the prior year.

Prime Medicine reports a net loss of $49.1 million for Q1 2026, with increased G&A expenses due to arbitration, while R&D costs decrease as the company prioritizes its in vivo liver franchise.

Acorn Energy reported a 28.1% decrease in Q1 2026 revenue compared to Q1 2025, driven by lower hardware sales, but saw an improvement in gross margin due to a higher proportion of monitoring revenue.

Sabre Corporation announced its first quarter 2026 financial results, showing an 8% increase in revenue to $760.3 million, but a significant decrease in net income compared to the prior year.